Ventilator-Associated Pneumonia
Ventilator-associated pneumonia (VAP) is a lung infection that occurs in people on mechanical ventilation in hospitals, typically affecting critically ill ICU patients and leading to increased morbidity and mortality, with a diagnosis requiring specific clinical and radiographic criteria. It is mainly caused by germs entering the lungs through ventilator tubes, and it notably prolongs ICU stays and has a death rate of up to 20-30%.
Health Outcomes
- Adverse Safety Concern from Antimicrobial Resistance
- Blocked Pneumococcal Binding Sites
- Detected Antimicrobial Resistance Genes
- Disrupted Bacterial Cell Membranes
- Elevated Antipneumococcal IgA Levels in Bronchoalveolar Lavage Fluid
- Elevated Viable Bacterial Counts
- Enhanced Antipneumococcal IgA Levels in BAL
- Enhanced Bacterial Growth
- Enhanced Immunity to Pneumococcal Infections
- Improved Airway Secretion Clearance
- Improved Bacterial Viability Under Stress
- Improved Immune Mechanisms Against S. pneumoniae
- Improved Pneumococcal Infection Outcomes
- Improved Resistance to Secondary Pneumococcal Pneumonia
- Improved Respiratory Mucosal Barrier Function
- Improved Treatment Safety
- Incidence of Late-Onset Sepsis
- Increased Adverse Events
- Increased Antagonistic Activity Against Undesirable Microorganisms
- Increased Anti-Pneumococcal Antibody Levels
- Increased Anti-Viral Factor Expression in Lung
- Increased Antibacterial Activity
- Increased Bacterial Survival
- Increased Post-Infection Lung Monocyte Levels
- Increased Resistance to Pneumococcal Infections
- Increased Risk of E. faecium Infection
- Inhibited NI1060 in Pasteurella
- Inhibited Pathogenic Microbes
- Modulated Pulmonary Innate Immune Microenvironment
- Modulation of Pulmonary Innate Immune Function
- No Significant Reduction in Lower Respiratory Tract Infections
- Preserved Anti-pseudomonal Activity
- Prevented Bloodstream Infection
- Reduced Bacteremia Incidence
- Reduced Clinical Sepsis
- Reduced Duration of Nosocomial Infections
- Reduced Infectious Complication
- Reduced Length of Intensive Care Unit Stay
- Reduced Mechanical Ventilation Duration
- Reduced Nosocomial Infection Incidence
- Reduced Nosocomial Infection Rate
- Reduced Pathogenic Bacteria Load
- Reduced Pathogenic Contamination
- Reduced Potential Pathogens
- Reduced Pseudomonas Levels
- Reduced SOFA Score
- Reduced Severity of Lung Injuries
- Reduced Side Infections in Preterm Newborns
- Reduced Ventilator-Associated Pneumonia
- Suppressed Pathogenic Growth
- Synergistic Antibiotic Effect